Search

Your search keyword '"Stefano Barco"' showing total 5 results
Start Over Author "Stefano Barco" Publisher springer science and business media llc
5 results on '"Stefano Barco"'

2. Increased interest in acute pulmonary embolism in Italy during the COVID-19 pandemic: a google trends-based analysis

Author

Loris Roncon, Stavros V. Konstantinides, Marco Zuin, Giovanni Zuliani, Stefano Barco, University of Zurich, and Roncon, Loris

Subjects
Internet, medicine.medical_specialty, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), business.industry, 10031 Clinic for Angiology, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 2720 Hematology, COVID-19, 610 Medicine & health, Hematology, medicine.disease, 2705 Cardiology and Cardiovascular Medicine, Pulmonary embolism, Italy, Pandemic, Emergency medicine, medicine, Humans, Pulmonary Embolism, Cardiology and Cardiovascular Medicine, business, Letter to the Editor, Retrospective Studies, COVID
Published
2020

4. Prevention and treatment of venous thromboembolism in patients with solid brain neoplasms: results of a survey among Italian physicians

Author

Stefano Barco, Andrea Fontanella, Marco Cei, Mauro Campanini, Nicola Mumoli, Francesco Dentali, Matteo Giorgi-Pierfranceschi, and Walter Ageno

Subjects
Adult, Male, medicine.medical_specialty, Consensus, 030204 cardiovascular system & hematology, Fondaparinux, Electronic mail, 03 medical and health sciences, 0302 clinical medicine, Solid brain cancer, Polysaccharides, Physicians, Surveys and Questionnaires, Internal medicine, Antithrombotic, Internal Medicine, medicine, Humans, Anticoagulants, Survey, Thromboprophylaxis, Venous thromboembolism, Emergency Medicine, cardiovascular diseases, Medical prescription, Intensive care medicine, Brain Neoplasms, business.industry, Heparin, Heparin, Low-Molecular-Weight, Middle Aged, Regimen, Italy, 030220 oncology & carcinogenesis, Concomitant, Female, Clinical Competence, business, Brain neoplasm, medicine.drug
Abstract

The decision concerning the introduction of primary and secondary prophylaxis of venous thromboembolism (VTE) in patients with solid brain neoplasms and brain metastases is often challenging due to the concomitant increased risk of intracranial hemorrhage and to limited evidence from available literature. A standardized questionnaire composed of nine multiple-choice questions regarding primary VTE prevention in non-surgical patients during high-risk conditions and VTE secondary prevention in patients with a solid brain neoplasm or cerebral metastases was sent via electronic mail to all the members (n = 2420) of the Italian Federation of the Internal Medicine Hospital Executives' Associations (FADOI) in June 2015. Three hundred and fifty two physicians (14.5%) returned it (participants' median age 51 years; females 46.9%). The majority of respondents prescribe primary thromboprophylaxis (usually with heparin) in non-surgical patients with solid brain neoplasms and brain metastases in concomitance with high-risk conditions. Full-dose anticoagulation with either low-molecular-weight heparin or fondaparinux is the preferred option for acute VTE (69.6%), while a reduced dose is chosen by 21.0% of physicians. The presence of a highly vascular brain neoplasm histotype mandates the prescription of a reduced-dose antithrombotic regimen in a minority of respondents. Vena cava filter placement is an option for the treatment of acute VTE in more than 6% of respondents. Anticoagulants are often prescribed for both VTE primary prevention and treatment. In conclusion, physicians' managements are partially in contrast to recent guidelines, reinforcing the need for educational programs and other studies in this setting.

Published
2016

5. Safety of low-dose subcutaneous recombinant interleukin-2: systematic review and meta-analysis of randomized controlled trials

Author

Kurt Quitzau, Christine Espinola-Klein, Marius Jankowski, Seyed Hamidreza Mahmoudpour, Luca Valerio, Stavros Konstantinides, Stefano Barco, and Christian Becker

Subjects
0301 basic medicine, medicine.medical_specialty, Injections, Subcutaneous, MEDLINE, lcsh:Medicine, chemical and pharmacologic phenomena, Placebo, Article, law.invention, 03 medical and health sciences, Clinical Trials, Phase II as Topic, 0302 clinical medicine, Randomized controlled trial, law, Neoplasms, Internal medicine, Recombinant interleukin-2, Humans, Medicine, Drug safety, lcsh:Science, Adverse effect, Randomized Controlled Trials as Topic, Multidisciplinary, Dose-Response Relationship, Drug, Adverse effects, business.industry, lcsh:R, Absolute risk reduction, Cancer, medicine.disease, Recombinant Proteins, Treatment Outcome, 030104 developmental biology, Clinical Trials, Phase III as Topic, Immune System Diseases, Meta-analysis, Interleukin-2, lcsh:Q, business, 030217 neurology & neurosurgery
Abstract

Standard-dose intravenous recombinant interleukin-2 (rIL-2) is indicated for the treatment of some subtypes of cancer; however, severe adverse events, including venous thromboembolism (VTE), may complicate its administration. Low-dose subcutaneous rIL-2 is being studied for the management of immune-mediated diseases, since it can modulate the immunological response by specifically targeting T regulatory (Treg) cells; importantly, it is supposed to cause fewer or no complications. In this systematic review and meta-analysis of phase II-III randomized controlled trials (RCTs), we investigated the safety of low-dose (

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results